CATALYSTTradingView • 6h ago
Merck & Company, Inc. Stock 12‑Month Price Target Raised to $157.72, Implies 8% UpsideTradingView report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
Why MRK Stock surged +2.18% Today — RQD Quant Desk Flash
$149.52 +2.18% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $150.47
Merck & Company Inc. (MRK) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (75% profit margin, 21% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $361.02B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on MRK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MRK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Merck & Company Inc. (NYSE: MRK) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $149.52 (+2.18% 1D, market cap $361.02B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, MRK ranks #35 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MRK compare to NVS and AZN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRK carries a Roarable B (75/100 RQD), trailing P/E of 19.8x, gross margin of 74.8%, and ROIC of 20.7%. By comparison, NVS (Novartis AG) holds a C+ grade (66/100 RQD, P/E 32.8x, ROIC 9.9%, cap $307.40B) and AZN (AstraZeneca PLC) posts a C grade (62/100 RQD, P/E 32.8x, ROIC 9.9%, cap $270.45B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MRK?
▼
Per MRK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000310158), Merck & Company Inc. generated $65.01B in revenue (+1.3% YoY), $18.25B in net income, and $12.36B in free cash flow against $136.87B in total assets and $46.75B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $150.46 (+0.63%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 19% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+7.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MRK)Realized 20D OHLCV Swing Band: ±6.7%
Deterministic 5-Pillar Attribution (75/100 Composite)
🔍 WHY MRK SCORES 75/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (21% of score)
Altman Z-Score 5.19 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (21% of score)
SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)
▼ #1 Drag / Risk Factor: Macro Regime Fit14/20 pts (-6 pt drag)
Macro rate sensitivity & RSI-14 (51.7) create a -6 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$141.98+4.5% Next Q
67
Q2 (-2Q)Grade B$148.30-4.4% Next Q
70
Q3 (-1Q)Grade B$141.82+5.4% Next Q
72
CurrentGrade B$149.52+7.4% Hist 90D α
75
Trajectory: B- (67) → B (75)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the MRK Bull Thesis Could Fail
Even with a 75/100 (B) score, MRK faces multiple-compression risk if 19.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 72.3% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($146.65) or 200D SMA ($127.07) invalidates the momentum regime and cuts Target Base ($160.96) toward Bear Floor ($122.61).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MRK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MRK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MRK Stock surged +2.18% Today — RQD Quant Desk Flash
Merck & Company Inc. (MRK) surged +2.18% to $149.52, trading at 90% of its 52-week range ($82.01 – $156.92). High-quality cash engine (75% profit margin, 21% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 90% of its 52-week range ($82.01 – $156.92) with RSI-14 at 51.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.7% around $149.52 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 74.8% gross margin and $12.4B annual free cash flow.
Live MRK Headlines & Catalysts
MARKET WIREYahoo Finance • 9h ago
Merck & Company, Inc. (MRK) Stock ForecastsYahoo Finance report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 12h ago
Merck & Company (MRK) Receives a Buy from GuggenheimThe Globe and Mail report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStockInvest.us • 15h ago
Merck Stock Price Forecast. Should You Buy MRK?StockInvest.us report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 21h ago
Merck appoints Paul Diaz to its board of directorsThe Globe and Mail report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
CATALYSTKalkine Media • 1d ago
Is Merck (NYSE:MRK) Stock A Bargain Despite Its Strong Rally?Kalkine Media report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Merck (MRK) Rallies 5.12% to $148.15 as Buyers Push Toward Upper Range - Synthetic Longhttps://www.siam.in/ report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 7h ago
Eli Lilly Jumped 6% After Earnings. It’s Up 68% in a Year. Where Does the Target Go Now?Mounjaro and Zepbound just handed Lilly a blowout quarter, but falling realized drug prices and one-time revenue boosts that won't repeat raise real questions about whether the rally holds from here.
CATALYSTYahoo • 8h ago
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?Bristol Myers Squibb gains 3% after beating third-quarter estimates, as its Growth Portfolio and promising pipeline support revenue prospects despite generic competition.
RISK WATCHYahoo • 9h ago
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026RAHWAY, N.J., November 02, 2026--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (MRK Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MRK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +32.19%📐 WEDGE COMPRESSION COIL
2026-11-02O $140.9H $149.5L $140.9C $149.5VOL 13.45M
RES: $153.5SUP: $140.2SMA50: $146.7SMA200: $127.1
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MRK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
13.3%/yr Implied 5Y Growth
vs. +1.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MRK today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MRK. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MRK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MRK)
Health Care Rank #35 of 1016
⚔️ NVS vs MRK Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MRK vs. NVS, AZN, ABBV, JNJ)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Merck & Company Inc. (MRK) ranks #35 by composite RQD confidence (75/100, grade B) and #5 by equity capitalization ($361.02B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while ABBV leads on capital efficiency and profitability with 29.0% ROIC and 70.2% gross margin. JNJ currently holds the highest overall quantitative score in the immediate peer group at 82/100 (A-) compared with MRK at 75/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MRK
ACTIVE
Merck & Company Inc. | B | 75/100 | 19.8x | 74.8% | 20.7% | +2.18% | $361.02B | Benchmark Subject |
| NVS Novartis AG | C+ | 66/100 | 32.8x | — | 9.9% | -0.19% | $307.40B | /nvs-vs-mrk → |
| AZN AstraZeneca PLC | C | 62/100 | 32.8x | — | 9.9% | +7.02% | $270.45B | /azn-vs-mrk → |
| ABBV AbbVie Inc. | A- | 81/100 | 121.6x | 70.2% | 29.0% | +1.41% | $513.86B | /abbv-vs-mrk → |
| JNJ Johnson & Johnson | A- | 82/100 | 24.7x | 67.9% | 25.5% | -0.73% | $662.49B | /jnj-vs-mrk → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000310158In its most recent audited fiscal period (FY2025, filed 2025-12-31), Merck & Company Inc. (MRK) reported GAAP revenue of $65.01B (+1.3% vs. FY2024 revenue of $64.17B , and +8.1% cumulative change since FY2023) , GAAP net income of $18.25B, operating cash flow of $16.47B, and free cash flow of $12.36B (-31.7% YoY). On the balance sheet, MRK closed FY2025 with $136.87B in total assets against $46.75B in total debt (Altman Z-Score: 5.19, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $65.01B | $18.25B | $16.47B | $12.36B | $136.87B | $46.75B |
| FY2024 (FY) | 2024-12-31 | $64.17B | $17.12B | $21.47B | $18.10B | $117.11B | $34.46B |
| FY2023 (FY) | 2023-12-31 | $60.12B | $365.0M | $13.01B | $10.30B | $198.56B | $46.46B |
3. MRK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MRK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Merck & Company Inc. (NYSE: MRK) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $149.52 (+2.18% 1D, market cap $361.02B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, MRK ranks #35 in composite RQD confidence.
How does MRK compare to NVS and AZN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRK carries a Roarable B (75/100 RQD), trailing P/E of 19.8x, gross margin of 74.8%, and ROIC of 20.7%. By comparison, NVS (Novartis AG) holds a C+ grade (66/100 RQD, P/E 32.8x, ROIC 9.9%, cap $307.40B) and AZN (AstraZeneca PLC) posts a C grade (62/100 RQD, P/E 32.8x, ROIC 9.9%, cap $270.45B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MRK?
Per MRK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000310158), Merck & Company Inc. generated $65.01B in revenue (+1.3% YoY), $18.25B in net income, and $12.36B in free cash flow against $136.87B in total assets and $46.75B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MRK trading relative to its 50-day, 200-day, and 52-week technical levels?
MRK last traded at $149.52 (+2.18% on volume of 12,345,387 shares), positioning the stock +1.96% above its 50-day simple moving average ($146.65) and +17.67% above its 200-day simple moving average ($127.07). Across its 52-week range of $82.01 to $156.92, MRK sits at the 90.1% percentile with a 14-day RSI of 51.7 (NEUTRAL RANGE) and an implied next-earnings move of ±6.7% ($139.50 to $159.54).
MRK Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MRK stock moving today?
Why MRK Stock surged +2.18% Today — RQD Quant Desk Flash. High-quality cash engine (75% profit margin, 21% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 75/100 (B)
✓ STAGE-C NUMBER FIREWALL VERIFIED
MRK — Merck & Company Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:08:48Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD score is 75 out of 100, graded B, with the verdict "Roarable Buy — Good Risk/Reward" (per the Roarable RQD rating). The five pillars break down as follows:
- Fundamental Cash Engine: 14 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 20.7% and an FCF yield of 3.42%. For a prospective investor, this indicates strong capital efficiency alongside a free-cash-flow yield that is modest relative to the stock price, so the cash generation is real but the valuation leaves less margin of safety on cash returns alone.
- Whale 13F Flow: 15 / 20. Per the Roarable RQD rating, this pillar scores institutional accumulation and options positioning. The score is positive but not top-tier, suggesting institutional interest is present without being overwhelming. Note that the holders section contains no 13F data in the source, so this pillar cannot be independently traced in this dossier.
- Insider Conviction: 16 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is among the stronger pillars, indicating insider-flow signals that lean supportive, though the underlying transactions are not itemized in the source data provided.
- Macro Regime Fit: 14 / 20. Per the Roarable RQD rating, this pillar uses a beta of 0.92 and sector sensitivity. A beta below 1.0 implies the stock has historically moved less than the broader market, which can appeal to investors seeking lower market sensitivity, though it does not guarantee performance in any given regime.
- Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, this pillar reflects an Altman Z-Score of 5.19, a Piotroski F-Score of 7/9, and a Debt/Equity ratio of 0.89. This is the strongest-scoring pillar and indicates a balance sheet that the rating system views as solid.
Taken together, the score suggests a financially sturdy company with strong returns on capital and supportive balance-sheet metrics, offset by a free-cash-flow yield and macro-fit scores that are less compelling. The valuation tradeoff is visible in the market data: a forward P/E of 18.4 and EV/EBITDA of 15.3 (per the market data) sit alongside a 3.42% FCF yield, meaning the investor is paying a meaningful multiple for the cash stream. Upside drivers in the source include the price-target commentary in the news wire; downside risk is concentrated in whether the cash engine can sustain its current yield at this price.
Snapshot
Business
Merck & Company Inc. is a NYSE-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry (per the profile). The company's gross margin of 74.8% and operating margin of 34.3% (per the market data) indicate a high-margin pharmaceutical profile. The source data does not itemize product lines, customer segments, or revenue-generation mechanics beyond these categorizations.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $65011.0M | $21539.7M | $18254.0M | N/A | $12360.0M | $14565.0M | $46750.0M |
| FY 2024 | $64168.0M | $20198.1M | $17117.0M | N/A | $18096.0M | $13242.0M | $34462.0M |
| FY 2023 | $60115.0M | $430.7M | $365.0M | N/A | $10300.8M | N/A | $46463.4M |
Per the SEC financials, revenue rose from $60115.0M in FY 2023 to $65011.0M in FY 2025, while net income moved from $365.0M to $18254.0M over the same span. Free cash flow declined from $18096.0M in FY 2024 to $12360.0M in FY 2025. Debt rose from $34462.0M to $46750.0M between FY 2024 and FY 2025. Per the Roarable RQD rating, the Altman Z-Score is 5.19 and the Piotroski F-Score is 7/9, with Debt/Equity at 0.89.
Recent Catalysts & News Wire Analysis
- Price-target raises (GREEN, CATALYST): Two TradingView items report 12-month price targets raised to $157.72 (implying 8% upside) and $157.48 (implying 10% upside).
- Guggenheim rating (YELLOW, MARKET WIRE): A Globe and Mail item reports a Buy rating from Guggenheim.
- Board appointment (YELLOW, MARKET WIRE): A Globe and Mail item reports Paul Diaz appointed to the board of directors.
- General forecast coverage (YELLOW, MARKET WIRE): Yahoo Finance and StockInvest.us items cover stock forecasts without further itemized detail.
- Risk watch: The source news items contain no itemized downside risk events. Proprietary signals in the Butterfly graph are empty (see below).
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. The only sector context is the Health Care classification and the Biotechnology: Pharmaceutical Preparations industry label (per the profile). The beta of 0.92 (per the market data) is the sole quantitative indication of market co-movement.
Open Questions
- What is the composition of the revenue base and which product lines drive the FY 2025 growth from $60115.0M to $65011.0M?
- What explains the decline in free cash flow from $18096.0M in FY 2024 to $12360.0M in FY 2025, and is it expected to recover?
- What drove the sharp difference between FY 2023 net income of $365.0M and operating income of $430.7M, and whether it reflects one-time items?
- Which institutional holders and insider transactions underlie the Whale 13F and Insider Conviction pillar scores?
- What supply-chain dependencies, if any, exist, given that the Butterfly graph records none?
MRK Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Merck & Company Inc. (MRK) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST TradingView • 6h ago
Merck & Company, Inc. Stock 12‑Month Price Target Raised to $157.72, Implies 8% Upside TradingView report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 9h ago
Merck & Company, Inc. (MRK) Stock Forecasts Yahoo Finance report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 12h ago
Merck & Company (MRK) Receives a Buy from Guggenheim The Globe and Mail report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 15h ago
Merck Stock Price Forecast. Should You Buy MRK? StockInvest.us report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 21h ago
Merck appoints Paul Diaz to its board of directors The Globe and Mail report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Kalkine Media • 1d ago
Is Merck (NYSE:MRK) Stock A Bargain Despite Its Strong Rally? Kalkine Media report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Merck (MRK) Rallies 5.12% to $148.15 as Buyers Push Toward Upper Range - Synthetic Long https://www.siam.in/ report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo • 7h ago
Eli Lilly Jumped 6% After Earnings. It’s Up 68% in a Year. Where Does the Target Go Now? Mounjaro and Zepbound just handed Lilly a blowout quarter, but falling realized drug prices and one-time revenue boosts that won't repeat raise real questions about whether the rally holds from here.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
MRK Bull vs. Bear Conversation Board — What's Your Call at $149.52?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MRK 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $172.67 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is MRK (B • RQD 75/100) a Buy at $146.33?
Welcome to the MRK (Merck & Company Inc.) Roar Pit. Current RQD Composite is 75/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (20.7% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $119.99 (-18.0%)
Spot @ $146.33 Pump the brakes on MRK — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on MRK, but look at what you are paying: 19.8x trailing P/E with 74.8% gross margins. Unless Merck & Company Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $169.74 (+16.0%)
Spot @ $146.33 MRK cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on MRK, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $146.33 (52-wk range $82.01 - $156.92), any beat on forward guidance forces shorts and underweight funds to chase.